Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judit Moldvay

Showing results (1-10 of 104) with videos related to

Pageof 11
Sort By:
Magyar Onkologia|June 7, 2002
[Tumor markers and prognostic factors of the primary lung cancer]Judit Moldvay
Magyar Onkologia|September 23, 2020
[Genomic studies to better understand the biological behavior of lung cancer]Judit Moldvay
Magyar Onkologia|October 9, 2007
[Financial aspects of targeted therapy of lung cancer as compared to conventional chemotherapy]Judit Moldvay
Orvosi Hetilap|June 7, 2012
[Personalized therapy in non-small cell lung cancer: from diagnosis to therapy]Judit Moldvay
Pathology Oncology Research : POR|January 19, 2024
KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challengesJudit Moldvay, József Tímár
Magyar Onkologia|March 10, 2012
[EGFR tyrosine kinase inhibitors in lung cancer management: sensitivity and resistance]Judit Moldvay, István Peták
Magyar Onkologia|March 3, 2016
[Self defense instead of offense - Immunotherapy in lung cancer]Judit Moldvay, Gyula Ostoros
Magyar Onkologia|September 19, 2019
[Possibilities of immune checkpoint inhibitor therapy for patients with metastatic non-small cell lung cancer]Vanda Téglási, Judit Moldvay, Zoltán Szállási, et al.
Magyar Onkologia|September 21, 2017
[Molecular diagnostics of ALK-positive lung cancer]József Tímár, Gábor Lotz, Erzsébet Rásó, et al.
Oncoimmunology|March 6, 2024
Are tumor-associated carbohydrates the missing link between the gut microbiome and response to immune checkpoint inhibitor treatment in cancer?Zoltan Szallasi, Aurel Prosz, Zsofia Sztupinszki, et al.
Pageof 11

Showing results (1-10 of 104) with videos related to

Sort By:
Pageof 11
Magyar Onkologia|June 7, 2002
[Tumor markers and prognostic factors of the primary lung cancer]Judit Moldvay
Magyar Onkologia|September 23, 2020
[Genomic studies to better understand the biological behavior of lung cancer]Judit Moldvay
Magyar Onkologia|October 9, 2007
[Financial aspects of targeted therapy of lung cancer as compared to conventional chemotherapy]Judit Moldvay
Orvosi Hetilap|June 7, 2012
[Personalized therapy in non-small cell lung cancer: from diagnosis to therapy]Judit Moldvay
Pathology Oncology Research : POR|January 19, 2024
KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challengesJudit Moldvay, József Tímár
Magyar Onkologia|March 10, 2012
[EGFR tyrosine kinase inhibitors in lung cancer management: sensitivity and resistance]Judit Moldvay, István Peták
Magyar Onkologia|March 3, 2016
[Self defense instead of offense - Immunotherapy in lung cancer]Judit Moldvay, Gyula Ostoros
Magyar Onkologia|September 19, 2019
[Possibilities of immune checkpoint inhibitor therapy for patients with metastatic non-small cell lung cancer]Vanda Téglási, Judit Moldvay, Zoltán Szállási, et al.
Magyar Onkologia|September 21, 2017
[Molecular diagnostics of ALK-positive lung cancer]József Tímár, Gábor Lotz, Erzsébet Rásó, et al.
Oncoimmunology|March 6, 2024
Are tumor-associated carbohydrates the missing link between the gut microbiome and response to immune checkpoint inhibitor treatment in cancer?Zoltan Szallasi, Aurel Prosz, Zsofia Sztupinszki, et al.
Pageof 11